Biotech Values

[genisi]

Why is this one [A4 trial] the most significant of the three?

Because A4 trial is going to enroll asymptomatic old people at risk for AD, based on their biomarkers not genetics. This population compose the majority of potential future (sporadic AD) patients. DIAN and API* trials aim, to test subjects with rare familial forms of AD (autosomal-dominant AD).

*I think the API trial might enroll ApoE4 carriers too, still this is a genetic driven criterion.